Bioventus (BVS) Tax Expense: History & Chart

Bioventus Inc.(BVS)

Medical - Devices · Durham, NC

$13.26-0.26 (-1.89%)

Delayed quote: Oct 6, 2026, 12:00 PM EDT

About Bioventus Inc.

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Durham, NC

950 employees

www.bioventus.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Robert Claypoole

View full financials

Income Tax Expense

The latest quarterly tax expense is −$20.90 Million. Income tax expense is the amount a company pays in federal, state, and foreign income taxes based on its taxable income for the period.

Q2 FY2026 (2026-06-27).

EBT|Net Income|Free Cash Flow|Revenue|Income Statement

Tax Expense

BVS Tax Expense

$-20.90M

Reported quarterly tax expense; no daily interpolation. Q2 FY2026 (2026-06-27): $-20.90M.

-5763.14% over 10Y

Current Tax Expense

−$20.90M

−$20.90 Million

Q2 FY2026 · 2026-06-27

QoQ Growth

N/A

Historical Data

Quarters of data available

Quarterly Tax Expense History

Period	Tax Expense	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-27	−$20.90M	N/A	N/A
Q1 FY2026Period end 2026-03-28	$571.00K	N/A	N/A
Q4 FY2025Period end 2025-12-31	−$3.17M	N/A	N/A
Q3 FY2025Period end 2025-09-27	$664.00K	-36.22%	+12.73%
Q2 FY2025Period end 2025-06-28	$1.04M	N/A	N/A
Q1 FY2025Period end 2025-03-29	−$95.00K	N/A	N/A
Q4 FY2024Period end 2024-12-31	$550.00K	-6.62%	N/A
Q3 FY2024Period end 2024-09-28	$589.00K	N/A	-1.83%
Q2 FY2024Period end 2024-06-29	−$7.34M	N/A	N/A
Q1 FY2024Period end 2024-03-30	$907.00K	N/A	N/A
Q4 FY2023Period end 2023-12-31	−$750.00K	N/A	+84.51%
Q3 FY2023Period end 2023-09-30	$600.00K	+57.48%	N/A
Q2 FY2023Period end 2023-07-01	$381.00K	N/A	-69.37%
Q1 FY2023Period end 2023-04-01	−$146.00K	+96.98%	+97.16%
Q4 FY2022Period end 2022-12-31	−$4.84M	+83.60%	-77.65%
Q3 FY2022Period end 2022-10-01	−$29.52M	N/A	-3247.28%
Q2 FY2022Period end 2022-07-02	$1.24M	N/A	-27.42%
Q1 FY2022Period end 2022-04-02	−$5.13M	-88.33%	-6930.14%
Q4 FY2021Period end 2021-12-31	−$2.73M	-208.96%	N/A
Q3 FY2021Period end 2021-10-02	−$882.00K	N/A	N/A
Q2 FY2021Period end 2021-07-03	$1.71M	N/A	N/A
Q1 FY2021Period end 2021-04-03	−$73.00K	N/A	N/A
Q4 FY2020Period end 2020-12-31	$890.00K	+138.61%	N/A
Q3 FY2020Period end 2020-09-30	$373.00K	N/A	N/A
Q2 FY2020Period end 2020-06-30	−$110.00K	N/A	N/A
Q1 FY2020Period end 2020-03-31	$39.00K	N/A	N/A
Q4 FY2019Period end 2019-12-06	$892.00K	N/A	N/A
Q3 FY2019Period end 2019-12-06	$369.00K	N/A	N/A
Q2 FY2019Period end 2019-06-29	$157.50K	0.00%	N/A
Q1 FY2019Period end 2019-03-29	$157.50K	N/A	N/A
Q1 FY2016Period end 2016-03-31	$603.00K	N/A	N/A
Q1 FY2015Period end 2015-03-31	$369.00K	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.

Data as of June 27, 2026